Bone Cancer Articles & Analysis
24 news found
said Cecilia Edebo, CEO CELLINK. “At Ossiform We Print Bone™ and soon we expect to obtain an FDA approval for our first P3D Bone implant. ...
ByCELLINK
With expertise in antibody generation and immunoassay development, Creative Diagnostics can generate various diagnostic antibodies covering a wide range of diseases, including infectious diseases, cardiovascular diseases, cancer and bone diseases, especially osteoporosis. In addition, Creative Diagnostics possesses a variety of ELISA kits for the detection of ...
Denosumab is an antibody treatment that shows a strong bone resorption inhibitory effect by targeting the RANKL protein, which is essential for the survival and function of osteoclasts. The original products are Amgen’s osteoporosis treatment Prolia (denosumab 60 mg), a treatment to prevent skeletal complications, and XGeva (denosumab 120 mg), a treatment for giant cell ...
” About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. ...
Of TSS50 responders at week 24, 28% (28/100) also showed at least a 1-grade improvements in bone marrow fibrosis and/or a 20% or greater reduction in the frequency of the variant allele. ...
Yair Halpern of Bnei Zion Medical Center, Haifa, Israel on renal cancer cryoablation and from Dr. Ghizlane Touimi Benjelloun of CHU de Nîmes, France on cryoablation of adrenal gland and vertebral metastasis. Scientific Presentation: Cryoablation of Low-Risk Breast Cancer An Update of the ICE3 Trial Dr. Kenneth R. Tomkovich, Co-Primary Investigator of the ...
The abstract titled “The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device” analyzes data collected using both SOZO and DXA in healthy participants and cancer patients. ...
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage cancer therapy Study is targeting Stage 4 breast cancer patients who ...
” About IceCure Medical Founded in 2006, Israel-based IceCure Medical (NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. ...
(NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. ...
Bone metastases are common among cancer patients and occur when cells from the primary cancerous tumor relocate to the bone. When these cancers relocate, they can cause changes to the bone, damaging it in a process called osteolysis. ...
This is an important inflection point for the company as we work towards establishing a regulatory path to make the ProSense System available in other major markets, such as the United States, China, and Japan as a minimally invasive treatment to early-stage breast cancer patients. I look forward to supporting existing and new employees so that we may meet the significant market ...
(NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in ...
“The Polish healthcare system is known for providing advanced cancer treatment and adopting new therapies and technologies. As breast cancer continues to be one of the most common types of cancer among Polish women, with a reported 24,644 women diagnosed in 20201, Poland has joined the global effort to increase breast ...
“We are excited to announce the advancement of our regulatory strategy for the IceSense3 system in China, as we look to bring our minimally-invasive therapy to more cancer patients around the world. With more than 400,000 new breast cancer cases diagnosed in China in 2020, according to the World Health Organization, breast cancer continues ...
Richard Fine will be presenting his findings on cryoablation at the upcoming Mayo Clinic School of Continuous Professional Development Conference “Breast Cancer Care: Innovation, Disruptive Technologies and Early Adopters 2021” in Rochester, MN on Friday, September 17, 2021. ...
Its four medical centers – Kapiolani, Pali Momi, Straub, and Wilcox – specialize in innovative programs in women’s health, pediatric care, cardiovascular services, cancer care, bone, and joint services, and more. Hawaii Pacific Health’s employed physicians and advanced practice providers are unified under the Hawaii Pacific Health Medical ...
-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ Company’s ...
Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in the long bones of the leg, such as the femur and tibia, of young children and adolescents. ...
-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions private, ...